Navigation Links
Analysis Finds BYETTA® Associated with Lower Likelihood of Heart Failure Compared with Other Diabetes Therapies: Results Presented at ADA 2011
Date:6/24/2011

SAN DIEGO, June 24, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced results from a retrospective analysis of more than 778,000 patients that showed the addition of BYETTA® (exenatide) injection to pre-existing diabetes treatment regimens was associated with a reduced likelihood of heart failure, especially among patients receiving insulin. These findings will be presented in a poster session at the 71st Scientific Sessions of the American Diabetes Association in San Diego on June 25 from 11:30 a.m. to 1:30 p.m. PDT.

The retrospective analysis used data from the GE Healthcare Centricity electronic medical record to analyze the likelihood of heart failure for BYETTA in combination with certain other diabetes treatments compared with control groups of patients not treated with BYETTA. Across all therapies, patients who received BYETTA were 54 percent less likely to experience heart failure compared to patients not treated with BYETTA.

"Compared with the general population, people with diabetes have an increased risk of heart disease, with at least double the risk of developing heart failure. That's why it is imperative that we understand the role diabetes treatments may play in patients' cardiovascular health," said Christian Weyer, M.D., senior vice president, research and development, Amylin Pharmaceuticals. "In addition to retrospective analyses like this one, our EXSCEL cardiovascular outcomes study is underway to thoroughly and prospectively evaluate cardiovascular effects of exenatide."

EXSCEL (EXenatide Study of Cardiovascular Event Lowering) is designed to determine if there are favorable cardiovascular effects of exenatide treatment, using BYDUREON™ (exenatide extended-relea
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.; Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
3. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
4. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
5. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
6. New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients
7. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
8. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
9. Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
10. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
11. Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... 4, 2015 UPM Pharmaceuticals, a division of ... Sprout Pharmaceuticals to manufacture Flibanserin 100 mg tablets. Sprout ... the first drug approved to treat hypoactive sexual desire ... dysfunction. The tablets will be manufactured at ... Tennessee . Dr. John M. ...
(Date:3/4/2015)... 4, 2015 Following the reintroduction of ... Center (LAC) released a report today urging policymakers ... and heroin epidemic through more effective use of ... "The Case for Expanding Access to Medication-Assisted Treatment ... the health, justice, and economic advantages of medication-assisted ...
(Date:3/4/2015)... 2015  Heska Corporation (Nasdaq: HSKA ) ... Join Its Fourth Quarter and Year End 2014 Earnings ... 9:00 a.m. (MST) / 11:00 a.m. (EST)Where: www.heska.com ... Call link on the front page of this website)How:Live ... web at the address above.  Alternatively, you may use ...
Breaking Medicine Technology:UPM Pharmaceuticals to Manufacture Sprout Pharmaceuticals' Flibanserin Tablets 2UPM Pharmaceuticals to Manufacture Sprout Pharmaceuticals' Flibanserin Tablets 3Improved Medication-Assisted Treatment Policy Could Aid Epidemic of 20 Million Americans with Untreated Addiction 2Webcast Alert: Heska Announces Fourth Quarter and Year End 2014 Earnings Conference Call Webcast 2
... , MELVILLE, N.Y. , Jan. 25 ... provider of health care products and services to office-based practitioners, announced today ... and Chief Financial Officer, will present at the Jefferies 2010 Global Healthcare ... Schein,s presentation is scheduled to begin at 3:30 p.m. EST ...
... , , RYE, N.Y. , ... a drug research and development company focused on the treatment of neurological ... clinical trials for CM-AT, its autism treatment, at ten sites across the ... New York City Drexel University , Philadelphia ...
Cached Medicine Technology:Henry Schein To Present At The Jefferies 2010 Global Healthcare Services Conference 2Curemark Enrolling Patients In Phase III Autism Trials At Ten Sites 2Curemark Enrolling Patients In Phase III Autism Trials At Ten Sites 3Curemark Enrolling Patients In Phase III Autism Trials At Ten Sites 4
(Date:3/4/2015)... Vancouver chiropractic clinic, Backs in Action ... the prestigious Vancouver Courier “Stars of Vancouver” 2015 ... company secured third place in the “Best Chiropractor” ... Massage Therapist” category. , As one of ... Vancouver Courier is a semiweekly local newspaper published ...
(Date:3/4/2015)... 04, 2015 " Optrix by Body ... its monthly Tech Report, which takes a look at ... to consumers. Scott Steinberg, a special reporter for NewsWatch ... shared with viewers how they have an ultra-rugged, waterproof ... industry is a major player at the Consumer Electronics ...
(Date:3/4/2015)... March 04, 2015 The Global ... billion in 2014 and is estimated to grow ... of 4.0% from 2014 to 2019. , Browse ... Market for an analysis of industry trends, segments ... global liquefied petroleum gas market is classified into ...
(Date:3/4/2015)... Organic Valley, the nation’s largest cooperative of ... cause campaign to Save the Bros, http://savethebros.com/ with ... difference to Bros everywhere. To date, the video has ... The video was named Adweek’s best commercial of the week ... Digiday, among other media outlets. , “We are pleased ...
(Date:3/4/2015)... Columbus is no stranger to drug addiction. The ... addiction, and suffers from the potential threat of Kratom. In ... DEA revealed that Kratom is a “drug of concern.” Although ... introduced herb from Southeast Asia acts as a stimulant in ... kratom foments symptoms similar to heroin withdrawal, and includes tremors, ...
Breaking Medicine News(10 mins):Health News:Backs in Action Receives Two Awards in The Vancouver Courier Readers’ Choice Awards 2015 2Health News:A Waterproof Phone Case with an Interchangeable Lens System was Featured on NewsWatch Television on January 30, 2015 2Health News:The Global Liquefied Petroleum Gas Market is Estimated to Reach $288.7 Billion by 2019 - A Report by MicroMarket Monitor 2Health News:The Global Liquefied Petroleum Gas Market is Estimated to Reach $288.7 Billion by 2019 - A Report by MicroMarket Monitor 3Health News:ORGANIC VALLEY URGES PUBLIC TO SAVE THE BROs: CAMPAIGN EARNS MORE THAN 1M VIEWS ON YOUTUBE 2Health News:ORGANIC VALLEY URGES PUBLIC TO SAVE THE BROs: CAMPAIGN EARNS MORE THAN 1M VIEWS ON YOUTUBE 3Health News:Columbus, OH Combats the Sale of Kratom as a Drug, Harbor Village Detox Stresses Caution 2
... , , IRVINE, Calif., Aug. ... share of $0.49 for the quarter ended June 30, 2009, a 24% ... The Company reported quarterly revenues of $81 million, a 4% increase compared ... , The Company,s results are reflective of improved growth ...
... an increased risk of death, found a new study of ... in CMAJ ( Canadian Medical Association Journal ) ... approximately 25% of people (both men and women) living in ... develop a spine fracture will die over a 5 year ...
... ... their already booming empire of top physicians. The much awaited International Association of Dermatologists ... their renowned directory, "The Leading Physicians Of the World". , ... New York, NY (PRWEB) August 3, 2009 ...
... , , CHICAGO, Aug. 3 Eczema ... rashes. It is commonly known as "the itch that rashes." (1) ... appears to result from a complex interaction of factors including personal and ... Scratching the affected area can lead to more itch, redness, swelling, ...
... Commentary by Betsy McCaughey ,rife with gross, cruel distortions, ... York State Director Lois Aronstein issued the following statement in response to ... reform measures passed or currently being considered by Congress. , , ... various media outlets is rife with gross -- and even cruel -- ...
... , , , ... N.C., Aug. 3 Kowa Research Institute (KRI) based in ... specialty pharmaceutical company headquartered in Montgomery, AL, announced today that ... (R) (pitavastatin), a potent HMG-CoA reductase inhibitor (statin), for ...
Cached Medicine News:Health News:CorVel Announces Revenues and Earnings 2Health News:CorVel Announces Revenues and Earnings 3Health News:CorVel Announces Revenues and Earnings 4Health News:CorVel Announces Revenues and Earnings 5Health News:Hip and back fractures increase mortality rates in people older than 50 2Health News:Top Dermatologists to be Selected and Published in "The Leading Physicians of the World" Consumer Directory. 2Health News:Five Questions About Eczema 2Health News:Five Questions About Eczema 3Health News:Five Questions About Eczema 4Health News:Five Questions About Eczema 5Health News:AARP Responds to Health Reform Scare Tactics 2Health News:AARP Responds to Health Reform Scare Tactics 3Health News:FDA Approves LIVALO(R) for Primary Hypercholesterolemia and Combined Dyslipidemia 2Health News:FDA Approves LIVALO(R) for Primary Hypercholesterolemia and Combined Dyslipidemia 3Health News:FDA Approves LIVALO(R) for Primary Hypercholesterolemia and Combined Dyslipidemia 4
The Medtronic EOPA CAP® arterial cannula provides a simple solution to obtaining accurate arterial pressure readings....
Intermittent catheter...
Intermittent catheter...
... new dimension in vitreoretinal surgery. ,By ... of purified perfluoro-n-octane, you can greatly ... ideal for managing retinal detachments complicated ... and trauma. , ,Certified to be ...
Medicine Products: